Continuous Glucose Monitoring in Diabetes and Prediabetes

Completed · Not applicable

Conditions studied: Diabetes Mellitus, Type 2, PreDiabetes, Obesity

In brief

Evaluate the use of brief serial real time continuous monitoring (RT-CGM) as a behavior modification tool in obese patients with prediabetes and diabetes. After receiving RT-CGM, nutrition and exercise education, participants will be able to monitor their blood sugar in real time for 2 sessions . Education on how to interpret CGM in the setting of food choices and exercise coupled with nutrition and exercise information should lead to improved weight and other nutritional and exercise changes.

Key facts

Study ID

NCT03805412

Run by

Nicole Ehrhardt, MD

People needed

23

Starts

2019-01-10

Expected to finish

2020-07-03

Last updated by the study team

2023-03-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-55
• Prediabetes (A1c 6.0-6.4) or Diabetes (A1c 7.0-10)
• BMI ≥ 30 kg/m2
• Willing to wear pedometer during study period
• Able to walk 2 city blocks at baseline without assistance (self-reported)
• Reading level at least 6th grade in English
• Expected to remain in local community for at least 4 months
• Either is not treated with or has been on a stable treatment regimen of any of the following medications for a minimum of 3 months prior to Visit 1 (Screening/Enrollment):
• Sulfonylureas
• Biguanidine
• Thyroid replacement therapy
• Glp-1 agonists
• Sodium-glucose co-transporters
• Basal insulin
• Thiazolidinediones
• Hormone replacement therapy (female subjects) estrogen/progesterone products
• Oral contraceptives/birth control (female subjects)
• Antidepressant agents (SSRIs, Paxil, Prozac, Celexa, Zoloft, etc.)
• Is able to read, understand, and sign the Informed Consent Form (ICF) and if applicable, an Authorization to Use and Disclose Protected Health Information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.

You may not qualify if…

• Women who are pregnant, lactating, planning to become pregnant
• Subjects who are taking amphetamines, anabolic, or weight-reducing agents
• Contraindications to moderate exercise
• Pre-prandial insulin
• On any antipsychotic medication or history of schizophrenia or bipolar disorder
• Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months
• Active wounds or recent surgery within 3 months
• Inflammatory disease, or chronic and current use of anti-inflammatory drugs or narcotics
• Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study
• Presence or history of severe congestive heart failure (New York Heart Association Class IV [CCNYHA 1994])
• Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant
• Enrolled in another weight loss program
• Already receiving continuous glucose monitoring (CGM)

Where it is running

• GWU Medical Faculty Associates — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.